Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.56 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.51 |
| ▸ | NOS2 | P35228 | 6/20 | 0.50 |
| ▸ | NOS1 | P29475 | 6/20 | 0.50 |
| ▸ | NOS3 | P29474 | 5/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ARG2 | P78540 | 4/20 | 0.44 |
| ▸ | ARG1 | P05089 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL29778163 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL30361345 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL288132 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL7928810 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL1791 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL28759066 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL31663499 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL1790 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL6374054 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL29518651 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389757-A2 | METHODS FOR PURIFYING ANTIBODIES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-26 | — | — | EP | claimed |
| US-20230046182-A1 | METHODS FOR PURIFYING ANTIBODIES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | claimed |
| CN-115607516-A | Medicine for preventing and treating cold or viral diseases | 刘力 | 2023-01-17 | — | — | CN | claimed |
| EP-3510042-A1 | METHODS FOR PURIFYING ANTIBODIES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-07-17 | — | — | EP | claimed |
| WO-2018047080-A1 | METHODS FOR PURIFYING ANTIBODIES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-03-15 | — | — | WO | claimed |
| US-20170112901-A1 | LIQUID PHARMACEUTICAL COMPOSITION OF CONJUGATED ERYTHROPOIETIN | INTAS PHARMACEUTICALS LTD. (IN) | 2017-04-27 | — | — | US | claimed |
| CN-106350485-A | Method for rapidly and efficiently separating individual antigen specific cell B | 杭州百凌生物科技有限公司 | 2017-01-25 | — | — | CN | claimed |
| CN-101781325-A | Gallium salicylaldehyde amino acid Schiff base quaternary coordination compound, preparation method and application thereof | UNIV BEIJING NORMAL | 2010-07-21 | — | — | CN | claimed |
| CN-1325063-C | L-amino acid water-soluble pearl powder and its preparing method | SONG TINGSHENG (CN) | 2007-07-11 | — | — | CN | claimed |
| CN-1709282-A | L-amino acid water-soluble pearl powder and its preparing method | SONG TINGSHENG (CN) | 2005-12-21 | — | — | CN | claimed |
| EP-1292609-A2 | PEPTIDES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BURKHOLDERIA CEPACIA | HERCULES INCORPORATED (US) | 2003-03-19 | — | — | EP | claimed |
| US-20020051819-A1 | Peptides, compositions and methods for the treatment of burkholderia cepacia | HERCULES INCORPORATED | 2002-05-02 | — | — | US | claimed |
| WO-2001098364-A2 | PEPTIDES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BURKHOLDERIA CEPACIA | HERCULES INCORPORATED (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2024151093-A1 | NOVEL LIQUID FORMULATION FOR PREVENTION OR TREATMENT OF THROMBOTIC DISEASE | 주식회사 녹십자 | 2024-07-18 | — | — | WO | disclosed |
| EP-4389757-A2 | METHODS FOR PURIFYING ANTIBODIES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-26 | — | — | EP | disclosed |
| CN-116694539-B | Lactobacillus plantarum J26 as direct vat set starter, and preparation method and application thereof | 东北农业大学 | 2023-11-17 | — | — | CN | disclosed |
| EP-0305387-A1 | INSULINOTROPIC HORMONE. | GEN HOSPITAL CORP (US) | 1989-03-08 | — | — | EP | disclosed |
| WO-1987006941-A1 | INSULINOTROPIC HORMONE | THE GENERAL HOSPITAL CORPORATION (US) | 1987-11-19 | — | — | WO | disclosed |
| US-4375399-A | REACTING A MIXTURE OF ACRYLAMIDE, POLYVINYL ALCOHOL, BOVINE ALBUMIN, GLUTARALDEHYDE AND AN ENZYME | Radelkis Elektrokemiai Miszergyarto Szovetkezet (HU) | 1983-03-01 | — | — | US | disclosed |
| US-4354913-A | MEMBRANE HAVING SURFACE CONTAINING THE REACTION PRODUCT OF GLUTARALDEHYDE AND THE ENZYME | RADELKIS ELEKTROKEMIAI MUSZERGYARTO SZOVETKEZET (HU) | 1982-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020051819-A1 | Peptides, compositions and methods for the treatment of burkholderia cepacia | NGLY1, VIP, CSTB | OTC 526/4885DDAH1 1832/4885NOS2 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.